Polycythemia vera: Difference between revisions
Jump to navigation
Jump to search
imported>Michael Benjamin No edit summary |
imported>Michael Benjamin No edit summary |
||
| Line 2: | Line 2: | ||
== JAK2 mutations == | == JAK2 mutations == | ||
<ref | <ref> Mutations in the JAK2 gene</ref>, specifically at the V617F locus, give rise to [[myeloproliferative syndromes|myeloproliferative disorders]] such as [[essential thrombocythemia]] and [[polycythemia vera]]. | ||
Authors <ref | Authors <ref>reported</ref> that other mutations of the coding region of the JAK2 gene could create a polycythemia phenotype. | ||
<ref name=Scott />Scott, et al. New Engl J Med 356: 459-468 2007. | <ref name=Scott />Scott, et al. New Engl J Med 356: 459-468 2007. | ||
Revision as of 01:13, 12 February 2007
Clinical criteria
JAK2 mutations
[1], specifically at the V617F locus, give rise to myeloproliferative disorders such as essential thrombocythemia and polycythemia vera.
Authors [2] that other mutations of the coding region of the JAK2 gene could create a polycythemia phenotype.
[3]Scott, et al. New Engl J Med 356: 459-468 2007. [4]James, et al. Nature 434:1144-8 2005.